Skip to main
OPRX
OPRX logo

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp demonstrated strong financial performance, with revenue increasing significantly by 30% year-over-year and consistently outperforming margin and earnings per share (EPS) expectations. The company is well-positioned for future growth, with projections indicating revenue growth in the high teens to low twenties, as the shift to digital interactions between pharmaceutical companies and healthcare providers continues to accelerate. Additionally, the robust visibility into 2025 revenue, with over 85% expected certainty, coupled with a favorable EBITDA guidance range that exceeds consensus estimates, further strengthens the outlook for OptimizeRx's financial trajectory.

Bears say

OptimizeRx Corp operates within the healthcare sector by delivering digital health messaging through electronic health records, enabling pharmaceutical companies to connect with healthcare providers and patients. Despite its innovative product offerings for patient engagement and medication adherence, financial reports may reflect declining revenues or increasing operational costs that adversely impact profitability. Furthermore, competitive pressures and regulatory challenges could hinder the company's growth potential, contributing to a negative outlook for its stock.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.